Firmonertinib
1L NSCLC with EGFR Exon 20 Insertion Mutations
Key Facts
About ArriVent Biopharma
Founded in 2021, ArriVent Biopharma identifies and in-licenses promising drug candidates from global innovation hubs, particularly China, to develop them for worldwide markets. The company's mission is to ensure differentiated medicines for difficult-to-treat cancers reach global patient populations. Led by a team with a proven track record in drug development and approvals, ArriVent's strategy leverages deep oncology expertise and regulatory experience to maximize the potential of its pipeline.
View full company profileAbout ArriVent Biopharma
Founded in 2021, ArriVent Biopharma identifies and in-licenses promising drug candidates from global innovation hubs, particularly China, to develop them for worldwide markets. The company's mission is to ensure differentiated medicines for difficult-to-treat cancers reach global patient populations. Led by a team with a proven track record in drug development and approvals, ArriVent's strategy leverages deep oncology expertise and regulatory experience to maximize the potential of its pipeline.
View full company profileAbout ArriVent Biopharma
Founded in 2021, ArriVent Biopharma identifies and in-licenses promising drug candidates from global innovation hubs, particularly China, to develop them for worldwide markets. The company's mission is to ensure differentiated medicines for difficult-to-treat cancers reach global patient populations. Led by a team with a proven track record in drug development and approvals, ArriVent's strategy leverages deep oncology expertise and regulatory experience to maximize the potential of its pipeline.
View full company profile